Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
Top Page
Merck & Company
(NYSE:MRK)
Select Model
Select Model
Rating:68Neutral
Price Target:
$127.00
▲(10.92% Upside)
Action:DowngradedDate:03/06/26
MRK scores as moderately attractive: strong underlying financial performance and a reasonable valuation are the primary positives. The score is held back by near-term earnings/catalyst risk from 2026 headwinds (one-time acquisition charge, Gardasil/RSV softness, and ~$2.5B generic/pricing impact) and a mixed technical picture with soft near-term momentum despite a longer-term uptrend.
Positive Factors
High profitability and margins
Merck's very high gross and net margins indicate durable pricing power and operational efficiency across pharmaceuticals, vaccines and biologics. Strong margins support sustained R&D investment, dividends and M&A capacity, allowing the company to fund long-term growth despite product transitions.
KEYTRUDA commercial resilience
KEYTRUDA's continued sales growth and broader indication uptake demonstrate durable oncology leadership and an expanding addressable market. Ongoing label expansions, earlier-stage adoption and planned QLEX IV-to-subQ conversion support a steady, long-term revenue base that cushions LOE on older assets.
Deep, de-risked pipeline and launch runway
A broad late-stage pipeline with numerous Phase III trials, readouts and near-term regulatory milestones provides structural growth optionality. Multiple de-risking events and new launches diversify future revenues, reducing dependence on legacy products and supporting durable top-line expansion over the next several years.
Negative Factors
Large one-time acquisition charge
The sizable non-deductible Sidera upfront charge materially reduces reported 2026 EPS and raises the effective tax rate, while associated financing increases other expense. This weakens near-term reported profitability and can constrain capital allocation flexibility until synergies and returns from the acquisition materialize.
Generics and pricing reforms headwind (~$2.5B)
Sustained revenue pressure from patent expirations, government pricing reforms and contract restructurings reduces predictable cash flows from legacy products. This structural erosion forces greater reliance on new launches and M&A to replace lost revenue and maintain long-term margin levels.
Vaccine demand softness (Gardasil, RSV)
Material declines in Gardasil sales (notably China and Japan) and weaker-than-expected RSV adoption reveal persistent commercial and demand risks in vaccines. Lower vaccine volumes and slower uptake increase the difficulty of sustaining revenue and margin contributions from this traditionally stable franchise.
Merck & Company (MRK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$283.09B
Dividend Yield3.12%
Average Volume (3M)11.48M
Price to Earnings (P/E)14.5
Beta (1Y)0.57
Revenue Growth1.59%
EPS Growth58.02%
CountryUS
Employees73,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)2.04
Shares Outstanding2,472,392,000
10 Day Avg. Volume9,244,508
30 Day Avg. Volume11,484,935
Financial Highlights & Ratios
PEG Ratio1.88
Price to Book (P/B)5.02
Price to Sales (P/S)4.06
P/FCF Ratio21.35
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue4.91
Enterprise Value/Gross Profit6.02
Enterprise Value/Ebitda12.12
Forecast
1Y Price Target
$131.08Price Target Upside14.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)5.12
Revenue Forecast (FY)$66.76B
Merck & Company Business Overview & Revenue Model
Company DescriptionMerck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
How the Company Makes MoneyMerck generates revenue primarily through the sales of its pharmaceutical products, which include a wide range of prescription medications and vaccines. The company’s revenue model is largely based on the development and commercialization of new drugs, which often involve extensive research and development (R&D) investments. Key revenue streams include the sales of its flagship products, vaccines, and biologics. Additionally, Merck engages in strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and government entities to enhance its R&D capabilities and accelerate product development. These partnerships may contribute to revenue through shared development costs and milestone payments. Furthermore, Merck benefits from a strong patent portfolio, which provides exclusivity for its products and helps maximize profit margins during the patent protection period. Overall, the company’s ability to innovate and bring new therapies to market, coupled with its established brand reputation, plays a crucial role in sustaining its earnings.
Merck & Company Key Performance Indicators (KPIs)
Any
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.
Data provided by:
The Fly
The FlyMerck & Company Earnings Call Summary
Earnings Call Date:Feb 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call balances near-term challenges (a sizable one-time Sidera acquisition charge, meaningful vaccine softness — notably Gardasil down 35% — RSV uptake below expectations, and an identified ~$2.5B headwind from generics and pricing reforms) against clear commercial and pipeline momentum (5% Q4 revenue growth, KEYTRUDA resilience, multiple high-growth product launches, strong specialty product performance, animal health growth, completed strategic acquisitions, and a materially expanded long‑term commercial opportunity with numerous near-term clinical readouts and regulatory milestones). While 2026 reported EPS and margins are being impacted by the acquisition charge and short-term pressures, management emphasizes durable long-term growth driven by a deep pipeline and new product launches, positioning the company for stronger growth beyond the LOE period.Q4-2025 Updates
Positive Updates
Solid Q4 Revenue Growth
Total company revenues of $16.4 billion, up 5% year-over-year (4% ex-FX) for the quarter; non-GAAP EPS of $2.04; gross margin at 79.7% (see margin drivers below).
KEYTRUDA Continued Strength
KEYTRUDA family sales of $8.4 billion, up 5% year-over-year driven by uptake in earlier-stage cancers and metastatic indications; US timing headwind of ~ $200 million noted; KEYTRUDA QLEX initial sales of $35 million with a permanent J-code expected in April and management targeting 30%–40% IV-to-QLEX adoption by 2028.
Material Pipeline and Long-Term Commercial Opportunity
Management cites line of sight to over $70 billion of potential commercial opportunity by the mid-2030s (up ~$20 billion YoY), more than double consensus 2028 KEYTRUDA peak; 21 potential new growth drivers identified with 10 expected to be substantially clinically de-risked over the next two years; 18 positive Phase III readouts and initiation of 21 Phase III trials in 2025.
Strategic Acquisitions and New Assets
Completed acquisitions of Sidera Therapeutics and Verona Pharma to expand respiratory and infectious disease portfolios; Sidera asset MK1406 (long-acting antiviral for influenza prevention) described as potentially first-in-class with >$5 billion revenue potential.
Strong Growth in Select Products
Wellyrec sales up 37% to $220 million (primarily U.S. advanced renal cell carcinoma uptake); WinRevair global sales $467 million with >1,500 U.S. new patients and >27,000 prescriptions dispensed; Cefaxib pneumococcal launch sales of $279 million; O2Ver (post-Verona) sales of $178 million with strong new patient starts and increased prescribing physicians.
Animal Health Momentum
Animal health sales increased 6% overall with livestock up 9%; companion animal sales were flat but supported by new launches (offset by reduced vet visits).
Clinical and Regulatory Milestones
Notable late-stage and regulatory progress: enlicitide Phase III results (oral PCSK9) with publications/acceptances (JAMA/NEJM); positive CADANCE Phase II for winravir supporting new indications; positive topline for islotrovir (HIV) and multiple Keytruda approvals/label expansions (including bladder cancer regimens and Keytruda SC approval in EU); several near-term PDUFA/readouts called out (HIV, oncology, cardiometabolic, ophthalmology).
2026 Revenue Guidance and Underlying Growth Drivers
2026 non-GAAP revenue guidance of $65.5–$67.0 billion (growth of 1%–3%, including ~1ppt positive FX); management expects growth driven by new launches, continued oncology strength, and animal health despite identified headwinds.
Negative Updates
Gardasil Revenue Decline
Gardasil sales of $1.0 billion in the quarter, down 35% year-over-year driven by materially lower demand in China and Japan (partially offset by price-driven U.S. growth of 7% and other international growth of 8%).
RSV Uptake Below Expectations
Inflonsia RSV sales were $21 million; initial uptake constrained by lower-than-expected infant immunization rates and elevated market inventory of RSV monoclonal antibodies.
Large One-Time Acquisition Charge Impacting 2026 Results
2026 guidance includes a one-time charge of approximately $9 billion related to the acquisition of Sidera (non-tax-deductible), which materially depresses reported EPS. Management noted 2026 EPS guidance midpoint of $5.08 (includes Sidera charge); excluding ~$3.65 per share upfront Sidera charge (and ~$0.03 ongoing costs), the midpoint would be $9.03 — indicating a sizable near-term earnings headwind.
Near-Term Commercial Headwinds (~$2.5B)
Management expects an approximate $2.5 billion headwind in 2026 from generic competition, IRA price setting, and the restructured agreement for Koselugo; generics primarily affect Januvia family, Bridion, and other products.
Margin and Inventory Pressure
Gross margin decreased by 1.1 percentage points to 79.7% in the quarter, attributed to higher inventory reserves partially offset by favorable product mix.
Soft Demand for Certain Products and Seasonality Risks
Significantly lower sales expected for Lagevrio (soft demand); RSV and certain vaccine seasonal dynamics and Medicare deductible seasonality may constrain early-year sales for recently acquired products; companion animal growth offset by fewer vet visits.
Company Guidance
Merck's 2026 non‑GAAP guidance calls for revenue of $65.5–$67.0 billion (growth of 1%–3%, including ~1 percentage‑point positive FX using mid‑January rates), an approximate gross margin of 82%, operating expenses of $35.9–$36.9 billion (which include a one‑time ~$9 billion upfront Sidera charge), other expense of ~ $1.3 billion (including financing costs for Sidera and Verona), a full‑year tax rate of 23.5%–24.5% (reflecting the non‑deductible Sidera charge), roughly 2.48 billion shares outstanding, and non‑GAAP EPS of $5.00–$5.15 (midpoint $5.08, including an estimated ~$0.10 FX benefit); excluding the ~$3.65/share Sidera upfront charge and ~$0.03/share of ongoing MK1406/transaction costs, the EPS midpoint would be ~$9.03. The company assumes about $3 billion of share repurchases, remains committed to the dividend, does not assume additional major business development in guidance, and notes an approximate $2.5 billion headwind from generics, IRA price setting and the restructured Koselugo agreement.Merck & Company Financial Statement Overview
Summary
Strong multi-year revenue growth and high profitability in 2024–2025 support a solid fundamentals score. However, the sharp 2023 earnings disruption, a 2025 leverage step-up (debt rising to ~$50.5B and debt/equity near ~1.0), and some variability in cash-flow conversion temper the overall financial quality.Income Statement
Revenue has grown strongly over the period (from ~$41.5B in 2020 to ~$65.0B in 2025), with very high gross profitability and solid operating profitability in the last two years. Profitability is strong in 2024–2025 (net margin ~26.7% to ~28.1%), but results were notably volatile in 2023 when earnings collapsed (net margin ~0.6%) before rebounding sharply—this swing lowers the quality/stability of the earnings profile despite the strong recent recovery.78
Positive
Balance Sheet
The company shows strong shareholder returns in most years (return on equity ~31%–37% in 2021–2022 and 2024–2025), but leverage is meaningful and has risen recently. Total debt increased materially from ~$38.3B (2024) to ~$50.5B (2025), pushing debt to equity close to ~1.0 in 2025. Equity has grown over time, but the combination of higher leverage and the 2023 profitability dip suggests a balance sheet that is solid, though not conservative.64
Positive
Cash Flow
Cash generation is consistently positive, with free cash flow remaining sizable across the cycle (about ~$5.8B to ~$18.1B). However, cash flow conversion is not consistently strong: operating cash flow is a modest share of operating profit (coverage roughly ~0.51–0.79), and free cash flow has declined in 2025 (about -5.3% growth) after a very strong 2024. Overall, cash flow supports the business, but shows some year-to-year variability and not-perfect translation from profits to cash.70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.01B | 64.17B | 60.12B | 59.28B | 48.70B |
| Gross Profit | 52.98B | 48.98B | 43.99B | 41.87B | 35.08B |
| EBITDA | 25.36B | 25.71B | 6.91B | 21.32B | 17.90B |
| Net Income | 18.25B | 17.12B | 365.00M | 14.52B | 13.05B |
Balance Sheet | |||||
| Total Assets | 136.87B | 117.11B | 106.67B | 109.16B | 105.69B |
| Cash, Cash Equivalents and Short-Term Investments | 14.56B | 13.69B | 7.09B | 13.19B | 8.10B |
| Total Debt | 50.53B | 38.27B | 36.27B | 31.98B | 34.63B |
| Total Liabilities | 84.20B | 70.73B | 69.04B | 63.10B | 67.44B |
| Stockholders Equity | 52.61B | 46.31B | 37.58B | 45.99B | 38.18B |
Cash Flow | |||||
| Free Cash Flow | 12.36B | 18.10B | 9.14B | 14.71B | 9.66B |
| Operating Cash Flow | 16.47B | 21.47B | 13.01B | 19.09B | 14.11B |
| Investing Cash Flow | -13.74B | -7.73B | -14.08B | -4.96B | -16.55B |
| Financing Cash Flow | -1.92B | -7.03B | -4.81B | -9.12B | 2.59B |
Merck & Company Technical Analysis
Neutral
114.50
Price Trends
114.64
Negative
105.00
Positive
92.77
Positive
Market Momentum
-0.18
Positive
44.31
Neutral
26.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRK, the sentiment is Neutral. The current price of 114.5 is below the 20-day moving average (MA) of 118.18, below the 50-day MA of 114.64, and above the 200-day MA of 92.77, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 44.31 is Neutral, neither overbought nor oversold. The STOCH value of 26.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MRK.
Merck & Company Risk Analysis
Merck & Company disclosed 31 risk factors in its most recent earnings report. Merck & Company reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Merck & Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $287.16B | 27.37 | 32.80% | 2.87% | 11.53% | -15.21% | |
74 Outperform | $175.40B | 17.46 | 41.01% | 2.52% | 2.76% | 6407.19% | |
73 Outperform | £221.39B | 28.13 | 23.00% | 1.53% | 10.20% | 40.57% | |
69 Neutral | $105.16B | -31.42 | 14.71% | 4.58% | -9.32% | 120.62% | |
68 Neutral | $283.09B | 14.46 | 36.19% | 3.12% | 1.59% | 58.02% | |
64 Neutral | $155.35B | 18.21 | 8.67% | 6.65% | 4.44% | 128.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
MRK
Merck & Company
114.50
23.78
26.21%
GILD
Gilead Sciences
141.29
36.57
34.92%
NVS
Novartis
149.81
40.39
36.92%
PFE
Pfizer
27.32
2.88
11.80%
SNY
Sanofi
43.71
-13.08
-23.03%
GB:AZN
AstraZeneca
14,276.00
2,693.86
23.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.